Advanced search
Publication Cover
Expert Review of Dermatology Volume 8, 2013 - Issue 6
Journal homepage
27
Views
2
CrossRef citations to date
0
Altmetric
Special Reports

Making proper judgement when choosing a treatment for actinic keratosis

Jan-Christoph SimonDepartment of Dermatology, Venereology, and Allergy, University of Leipzig, Philipp-Rosenthal-Straße 23, 04103 Leipzig, GermanyCorrespondence[email protected]
,
Bruce ThiersDepartment of Dermatology and Dermatologic Surgery, Medical University of South Carolina,USA
&
Matthias AugustinUniversity Medical Centre, Institute for Health Services Research in Dermatology & Healthcare (IVDP), Hamburg-Eppendorf,Germany
Pages 595-603 | Published online: 10 Jan 2014

References

  • Feldman SR, Fleischer AB Jr. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 87(4), 201–207 (2011).
  • Martin G. The impact of the current United States guidelines on the management of actinic keratosis: is it time for an update? J. Clin. Aesthet. Dermatol. 3(11), 20–25 (2010).
  • Criscione VD, Weinstock MA, Naylor MF et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 115(11), 2523–2530 (2009).
  • Berman B, Amini S. Pharmacotherapy of actinic keratosis: an update. Expert Opin. Pharmacother. 13(13), 1847–1871 (2012).
  • Stockfleth E, Ferrandiz C, Grob JJ et al. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur. J. Dermatol. 18(6), 651–659 (2008).
  • Thai KE, Fergin P, Freeman M et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int. J. Dermatol. 43(9), 687–692 (2004).
  • Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br. J. Dermatol. 165(5), 1101–1108 (2011).
  • Stockfleth E, Zwingers T, Willers C. Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses. Eur. J. Dermatol. 22(3), 370–374 (2012).
  • Dirschka T, Dominicus R, Lars K, Rodriguez R, Willers C, Simon JC. Long term efficacy and recurrence of topical 0.5% 5-fluorouracil with 10% salicylic acid for actinic keratosis compared to cryotherapy. A prospective, active controlled, randomized, exploratory study. Presented at: 8th European Association of Dermato-Oncology. Barcelona, Spain, 14–17 November 2012, 58 (Poster 91).
  • Cohen JL. Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J. Clin. Aesthet. Dermatol. 3(6), 39–44 (2010).
  • Schaefer I, Augustin M, Spehr C, Reusch M, Kornek T. Prevalence and risk factors of actinic keratoses in Germany – analysis of multisource data. J. Eur. Acad. Dermatol. Venereol. (2013) (Epub ahead of print).
  • Neidecker MV, Davis-Ajami ML, Balkrishnan R, Feldman SR. Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics 27(6), 451–464 (2009).
  • Housman TS, Feldman SR, Williford PM et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J. Am. Acad. Dermatol. 48(3), 425–429 (2003).
  • Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis 70 (2 Suppl.), 30–36 (2002).
  • Gold MH. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J. Drugs Dermatol. 7(1), 23–25 (2008).
  • Colombo GL, Chimenti S, Di Matteo S et al. Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system. G. Ital. Dermatol. Venereol. 145(5), 573–581 (2010).
  • Muston D, Downs A, Rives V. An economic evaluation of topical treatments for actinic keratosis. J. Dermatolog. Treat. 20(5), 266–275 (2009).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.